One Month Follow-up of Haemostatic Variables in Patients Undergoing Aortocoronary Bypass Surgery

Summary

It is already known that activation of the coagulation and fibrinolytic system occurs in patients undergoing cardiopulmonary bypass (CPB). We have thus studied twenty patients (10 treated with aprotinin during CPB and 10 untreated) both during the intraoperative period and during thirty days follow up. In untreated patients D-dimer levels increased 4-fold during CPB and the levels were above baseline for the whole follow up (p<0.0001). D-dimer levels were reduced in aprotinin treated patients in comparison to untreated patients (p = 0.0172); levels then gradually increased to the values of the untreated patients over the following 24 h later and remained higher during the thirty day follow up. The behavior of haemostatic variables in the 24 h after CPB did not vary between untreated and aprotinin treated patients. In particular, five minutes after protamine sulphate administration, levels of F1 + 2 and TAT rose significantly (p = 0.0054, p = 0.0022 respectively), whereas fibrinogen significantly decreased (p<0.0001) and PAI-1 antigen levels were reduced. Two days after CPB the concentrations of F1 + 2 and TAT lowered, whereas fibrinogen and PAI-1 antigen levels increased. On the 5th, 8th and 30th days after CPB, F1 + 2 and TAT levels remained higher than those reported at baseline in both groups of patients, whereas fibrinogen levels increased over basal levels in aprotinin treated patients only.

Thus, in addition to the activation of the coagulation and fibrinolytic system occurring during the intraoperative period, in patients undergoing CPB, there are alterations of haemostatic variables up to thirty days from surgery.

• References

• 1 Teufelsbauer H, Proidl S, Havel M, Vukovich Th. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis. Thromb Haemost 1992; 68: 250-252
• 2 Demeyere R. Coagulation in cardiac surgery. Current Opinion in Anaesthesiology 1990; 3: 77-85
• 3 Boisclair MD, Philippou H, Lane DA. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers. Blood Coagulation and Fibrinolysis 1993; 4: 1007-1021
• 4 Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment FI + 2. Thromb Haemost 1993; 70: 253-258
• 5 Stibbe J, Kluft C, Brommer EJP. Gomes M, De JongD, Nauta J. Enhanced fibrinolytic activity during cardiopulmonary bypass in open-heart surgery in man is caused by extrinsic (tissue-type) plasminogen activator. EurJ Clin Invest 1984; 14: 375-382
• 6 Kucuk O, Kwaan HC, Frederickson J, Wade L, Green D. Increased fibrinolytic activity in patients undergoing cardiopulmonary bypass operation. Am JHematol 1986; 23: 223-229
• 7 Boisclair MD, Lane DA, Wilde JT, Ireland H, Preston FE, Ofosu FA. A comparative evaluation of assays for markers of activated coagulation and/or fibrinolysis: thrombin-antithrombin complex, D-dimer and fibrino- gen/fibrin fragment E antigen. Br J Haematol 1990; 74: 471-479
• 8 Muller M, Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing, cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991; 101: 968-972
• 9 Gram J, Janetzko T, Jespersen J, Bruhn HD. Enhanced effective fibrinolysis following the neutralization of heparin in open heart surgery increases the risk of post-surgical bleeding. Thromb Haemost 1990; 63: 241-245
• 10 de Smet AA E A, Joen MC N, van OeverenW, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CR H. Increased anticoagulation during cardiopulmonary bypass by aprotinin. J Thorac Cardiovasc Surg 1990; 100: 520-527
• 11 Hunt BJ, Segal H, Yacoub M. Aprotinin and heparin monitoring during cardiopulmonary bypass. Circulation 1992; 86 (02) 410-412
• 12 van OeverenW, Jansen NJ G, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR H. Effects of aprotinin on haemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987; 44: 640-645
• 13 Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effect of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991; 101: 958-967
• 14 Mohr R, Goor DA, Lusky A, Lavee J. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction: a scanning electron microscope study. Circulation 1992; 86 (02) 405-409
• 15 Orchard MA, Goodchild CS, Prentice CR M, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, Michelson AD. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-541
• 16 Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant. Thromb Haemost 1993; 70: 259-262
• 17 Verstraete M, Brown BG, Chesebro JH, Ekestrom S, Harker LA, Henderson AH, Jewitt DE, Oliver MF, Sleight P. Evaluation of antiplatelet agents in the prevention of aorto-coronary bypass occlusion. Eur Heart J 1986; 7: 4-13
• 18 Buring JE, Hennekens CH. Antiplatelet therapy to prevent coronary artery bypass graft occlusion. Editorial comment Circulation 1990; 82: 1046-1048
• 19 ACC/AHA guidelines and indications for coronary artery bypass graftsurgery. A report of the American College of Cardiology/American Heart Association Task Force on assessment of diagnostic and therapeutic cardiovascular procedures. Circulation 1991; 83 (03) 1125-1173
• 20 Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, Regnier O, Legrand Y, Caen JP. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Thromb Haemost 1991; 66: 633-637
• 21 Prentice CR M, Mc NicolG, Douglas AS. Studies on the anticoagulant action of aprotinin (Trasylol). Thromb Diath Haemorrh 1970; 24: 265-272
• 22 Orchard MA, Urquhart S, Prentice CR M. Aprotinin enhances the anticoagulant effect of heparin in vitro. Br J Haematol 1990; 76: 25
• 23 Tripodi A, Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of prothrombin fragment 1 + 2 values measured by two commercial ELISA methods: influence of different anticoagulants and standards. Thromb Haemost 1994; 71: 605-608
• 24 Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993; 55: 552-559
• 25 Downing SW, Edmunds Jr LH. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg 1992; 54: 1236-1243
• 26 Nilsen DW, Almdahl SM, Svensson B, Vaage J, Rasmussen K, Østerud B. Lipopolysaccharide induced monocyte thromboplastin synthesis and coagulation responses in patients undergoing coronary bypass surgery after preoperative supplementation with n-3 fatty acids. Thromb Haemost 1993; 70: 900-902